{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:02:58Z","timestamp":1762866178632},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T00:00:00Z","timestamp":1372982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00066-013-0378-2","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T10:44:55Z","timestamp":1372848295000},"page":"625-631","source":"Crossref","is-referenced-by-count":10,"title":["Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck"],"prefix":"10.1007","volume":"189","author":[{"given":"C.","family":"Matuschek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"B\u00f6lke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Henke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Stegmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Welz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gioules","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Volk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Budach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Budach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,5]]},"reference":[{"key":"378_CR1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0360-3016(96)00614-1","volume":"37","author":"Al-Sarraf","year":"1997","unstructured":"Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88\u201324. Int J Radiat Oncol Biol Phys 37:777\u2013782","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"378_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00066-011-0006-y","volume":"188","author":"Alongi","year":"2012","unstructured":"Alongi F, Bignardi M, Garassino I et al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 188:49\u201355","journal-title":"Strahlenther Onkol"},{"key":"378_CR3","first-page":"Abstr","volume":"29","author":"Ang","year":"2011","unstructured":"Ang K (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III\u2013IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:Abstr. 5500","journal-title":"J Clin Oncol"},{"key":"378_CR4","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","volume":"28","author":"Argiris","year":"2010","unstructured":"Argiris A, Heron DE, Smith RP et al (2010) Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 28:5294\u20135300","journal-title":"J Clin Oncol"},{"key":"378_CR5","first-page":"830","volume":"351","author":"Bernier","year":"2004","unstructured":"Bernier J (2004) Canc EORT. Treatment of advanced head and neck cancer\u2014Reply. N Engl J Med 351:830\u2013831","journal-title":"N Engl J Med"},{"key":"378_CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00066-008-1829-z","volume":"184","author":"Bolke","year":"2008","unstructured":"Bolke E, Gerber PA, Lammering G et al (2008) Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184:105\u2013110","journal-title":"Strahlenther Onkol"},{"key":"378_CR7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21\u201328","journal-title":"Lancet Oncol"},{"key":"378_CR8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMc071075","volume":"357","author":"Budach","year":"2007","unstructured":"Budach W, Bolke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514\u2013515","journal-title":"N Engl J Med"},{"key":"378_CR9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00066-011-0064-1","volume":"188","author":"Christiansen","year":"2012","unstructured":"Christiansen H, Rodel RM (2012) Neck dissection of the residually positive neck after primary radiochemotherapy for locally advanced head and neck cancer. Strahlenther Onkol 188:444\u2013445","journal-title":"Strahlenther Onkol"},{"key":"378_CR10","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"Cooper","year":"2004","unstructured":"Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937\u20131944","journal-title":"N Engl J Med"},{"key":"378_CR11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","volume":"84","author":"Cooper","year":"2012","unstructured":"Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198\u20131205","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"378_CR12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00066-012-0128-x","volume":"188","author":"Cvek","year":"2012","unstructured":"Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70\u201375\u00a0Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. Strahlenther Onkol 188:666\u2013670","journal-title":"Strahlenther Onkol"},{"key":"378_CR13","first-page":"693","volume":"167","author":"Fietkau","year":"1991","unstructured":"Fietkau R, Iro H, Grabenbauer GG et al (1991) Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors. Strahlenther Onkol 167:693\u2013700","journal-title":"Strahlenther Onkol"},{"key":"378_CR14","first-page":"13","volume":"170","author":"Fietkau","year":"1994","unstructured":"Fietkau R, Iro H, Tulusan AH et al (1994) Prognostic value of S-phase fraction in head and neck squamous cell carcinomas and nodal negative breast carcinomas. Strahlenther Onkol 170:13\u201324","journal-title":"Strahlenther Onkol"},{"key":"378_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.03.7234","volume":"24","author":"Fietkau","year":"2006","unstructured":"Fietkau R, Lautenschl\u00e4ger C, Sauer R et al (2006) Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: results of the German phase III trial ARO 96\u20133. J Clin Oncol 24:1","journal-title":"J Clin Oncol"},{"key":"378_CR16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091\u20132098","journal-title":"N Engl J Med"},{"key":"378_CR17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","volume":"90","author":"Giro","year":"2009","unstructured":"Giro C, Berger B, Bolke E et al (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90:166\u2013171","journal-title":"Radiother Oncol"},{"key":"378_CR18","first-page":"Abstract","volume":"30","author":"Jordi","year":"2012","unstructured":"Jordi G, Andre F, Ricard M et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 30:Abstract 5502","journal-title":"J Clin Oncol"},{"key":"378_CR19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.298.1.70","volume":"298","author":"Karamouzis","year":"2007","unstructured":"Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70\u201382","journal-title":"JAMA"},{"key":"378_CR20","first-page":"701","volume":"6","author":"Milas","year":"2000","unstructured":"Milas L, Mason K, Hunter N et al (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701\u2013708","journal-title":"Clin Cancer Res"},{"key":"378_CR21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/era.11.20","volume":"11","author":"Specenier","year":"2011","unstructured":"Specenier P, Vermorken JB (2011) Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 11:511\u2013524","journal-title":"Expert Rev Anticancer Ther"},{"key":"378_CR22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ijrobp.2007.06.076","volume":"69","author":"Thariat","year":"2007","unstructured":"Thariat J, Milas L, Ang KK (2007) Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69:974\u2013984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"378_CR23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/bjc.2011.152","volume":"104","author":"Vermorken","year":"2011","unstructured":"Vermorken JB, Guigay J, Mesia R et al (2011) Phase I\/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and\/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104:1691\u20131696","journal-title":"Br J Cancer"},{"key":"378_CR24","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, Herpen C van et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695\u20131704","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-013-0378-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-013-0378-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-013-0378-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:31:12Z","timestamp":1558578672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-013-0378-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,5]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1007\/s00066-013-0378-2","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,5]]}}}